Kamada Ltd. (NASDAQ:KMDA) Short Interest Declines 81.5% in January

Kamada Ltd. (NASDAQ:KMDA) experienced a notable reduction in short interest during January. As of January 31st, the short interest stood at 7,900 shares, reflecting an 81.5% decrease from the January 15th figure of 42,600 shares. Notably, only 0.0% of the company’s shares are currently sold short. Given an average daily trading volume of 141,600 shares, the days-to-cover ratio is a brief 0.1 days.

Kamada Stock Performance

During midday trading on Wednesday, Kamada shares rose by 1.1%, increasing by $0.09 to reach a price of $8.09. The trading volume for the day was 524,746 shares, which is higher than the typical volume of 294,030 shares. The company has a market capitalization of $465.01 million, with a P/E ratio of 28.89, a P/E/G ratio of 0.88, and a beta of 0.99. The stock's 50-day moving average is $6.67, while its 200-day moving average is $5.95. Over the past year, Kamada has seen a low of $4.74 and a high of $9.15.

Analyst Ratings Adjustments

In recent updates, HC Wainwright reaffirmed a "buy" rating for Kamada, setting a price target of $11.00 for its shares in a report published on January 10th.

Institutional Investments in Kamada

Various institutional investors have recently adjusted their holdings in Kamada. For instance, Geode Capital Management LLC increased its stake in the company by 5.6% during the fourth quarter, now owning 29,289 shares valued at approximately $178,000 after acquiring an additional 1,549 shares during this period. Additionally, JPMorgan Chase & Co. established a new position in Kamada worth about $67,000 in the same quarter. The Public Employees Retirement System of Ohio also bought a new stake in Kamada valued at around $77,000, while Plato Investment Management Ltd added approximately $117,000 worth of shares in the third quarter. Overall, institutional investors and hedge funds own about 20.38% of Kamada's stock.

Company Overview

Kamada Ltd. specializes in the manufacture and sale of plasma-derived protein therapeutics. Their commercial product offerings include KAMRAB/KEDRAB for rabies prophylaxis; CYTOGAM for Cytomegalovirus disease prophylaxis in organ transplants; VARIZIG for varicella post-exposure prophylaxis; WINRHO SDF for immune thrombocytopenic purpura; HEPAGAM B for preventing hepatitis B recurrence in liver transplants; GLASSIA for intravenous AATD; KAMRHO (D) IM for hemolytic disease of newborns; KAMRHO (D) IV for immune thrombocytopenic purpura; and snake bite treatments like Echis coloratus and Vipera palaestinae Antiserum.

Kamada, stock, shortinterest